Navigation Links
EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
Date:5/15/2009

er expanded its clinical development efforts for ENMD-2076 and has commenced a Phase 1 study in patients with relapsed or refractory leukemia. The study will be conducted at the Princess Margaret Hospital in Toronto, Ontario and Karen Yee, M.D., will serve as Principal Investigator. Although the primary endpoints of the study include defining the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of ENMD-2076 administered orally in patients with relapsed or refractory leukemia, the study will also evaluate pharmacodynamic effects of ENMD-2076 by collaborating with Dr. David Hedley, Department of Molecular Oncology, Ontario Cancer Institute (OCI).

Dr. Mark R. Bray, EntreMed Vice President, Research commented, "We are very excited to be working with Dr. Hedley and his staff, who have considerable experience in evaluating the mechanistic effects of kinase inhibitors like ENMD-2076 in cancer patients. The close proximity of EntreMed scientific personnel based in Toronto to our clinical collaborators at the OCI will facilitate our ability to obtain the maximum value from this study and its correlative components."

In addition, the U.S. Food and Drug Administration (FDA) granted orphan drug designation for ENMD-2076 for the treatment of ovarian cancer. Several ovarian cancer patients participated in the ENMD-2076 Phase 1 study in solid tumors and will be included in the data presentations at ASCO. Orphan drug is a designation by the Food and Drug Administration indicating a therapy developed to treat diseases that affect fewer than 200,000 persons in the United States. Sponsors of drugs granted orphan designation qualify for tax credit and marketing exclusivity incentives of the Orphan Drug Act. Previously EntreMed had received orphan drug designation for ENMD-2076 for multiple myeloma.

EntreMed Vice President and Chief Medical Officer, Carolyn F. Sidor, M.D., M.B.A., commented, "The clinical development
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
2. EntreMed to Present at the New York Society of Security Analysts Industry Conference
3. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
4. EntreMed Reports Third Quarter 2008 Financial Results
5. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
6. EntreMed to Present at BioPartnering Europe Conference
7. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
8. EntreMed Reports Second Quarter 2008 Financial Results
9. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
10. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
11. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... In recent years, growing suspicion about the ... development and promotion has led to unprecedented levels of ... concerns about the insidious impact of commercialization of research, ... to the world’s biggest pharmas for illegal marketing activities, ...
(Date:1/14/2014)... OTTAWA, Ontario , Jan. 14, 2014   Kinaxis ®, ... ( SCM ) and sales and operations planning ( S&OP ... the Biomanufacturing Summit , which will be held at ...  At the conference, join Kinaxis customer Elisabeth Kaszas , ...
(Date:1/14/2014)... 2014 During the 1600’s through the 1800’s ... Doctor’s Plague.” In this time period, doctors did not know ... times, to the death of vulnerable patients. In the same ... they may be unwittingly transmitting herpes viruses to their patients. ...
(Date:1/14/2014)... Holloway America today announced an addition to ... (MTRs) for all pressure vessels and tank parts the ... important for equipment that must meet ASME, CE, PED, ... functionality that allows authorized users to quickly locate and ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
... Symbol: MS , , , ... Medical Corp. (TSX: MS), today announced that the University of Alberta , a major shareholder ... , , Certain employees, officers ... Alberta . , , , ...
... Smartfield, ... was approved for $250,000 for completion and commercialization of their SmartCrop® technology. SmartCrop is ... , ... 30, 2010 -- Smartfield, Inc. is an information company that develops and ...
... ATLANTA , April 29 Xoft, Inc., developer of ... therapy directly to cancer sites with minimal radiation exposure to surrounding ... for the treatment of skin cancer. The announcement was made here ... April 29-May 1 . , ...
Cached Biology Technology:BioMS Medical updates University of Alberta equity position 2$250,000 Awarded to Smartfield, Inc. of Lubbock, TX by the Texas Emerging Technology Fund 2Xoft's Electronic Brachytherapy Hits Milestone With 10 New Skin Cancer Installations 2Xoft's Electronic Brachytherapy Hits Milestone With 10 New Skin Cancer Installations 3Xoft's Electronic Brachytherapy Hits Milestone With 10 New Skin Cancer Installations 4
(Date:4/22/2014)... 2014 Scientists from the Florida campus of The ... that plays a critical but previously unknown role in ... showed a novel role for a protein known as ... eLife , a publisher supported by the Howard ... Wellcome Trust. , "This is a critical building block ...
(Date:4/22/2014)... nanotechnology expert will present a poster titled ... 7th International Nanotoxicology Congress to be held ... Monita Sharma will outline a strategy consistent with the ... " Toxicity Testing in the 21st Century: A Vision ... methods involving human cells and cell lines for mechanistic ...
(Date:4/22/2014)... Experimental Biology (FASEB) has released updated factsheets ... the National Institutes of Health (NIH) benefits each of ... pleased to make these factsheets available to help citizens ... state," said FASEB President, Margaret K. Offermann, MD, PhD. ... research funding, investing $29.2 billion in FY 2013 in ...
Breaking Biology News(10 mins):Scientists identify critical new protein complex involved in learning and memory 2
... This press release is available in French ... and men contribute equally to the lineage of contemporary populations? ... polygamy or monogamy? To answer these questions, Dr. Damian Labuda, ... a professor at the Department of Pediatrics of the Universit ...
... professor of chemistry at New Jersey Institute of ... patent today for a novel composition of matter. ... (US Patent Number 7,670,684) discloses a new self-contained ... comprised of organic scaffolds with metal centers, which ...
... worldwide. It is the most common form of age-related dementia, ... no cure, and the available drugs only help to relieve ... characteristic changes in the brains of Alzheimer,s patients is the ... curing or at least slowing the disease lies in developing ...
Cached Biology News:Modern man found to be generally monogamous, moderately polygamous 2NJIT researcher awarded patent for hydrophobic, corrosion-resistant coating 2The sea squirt offers hope for Alzheimer's sufferers 2
Candida (IgG) -Ab EIA Sample Size: 5 l...
Candida (IgA) -Ab EIA Sample Size: 5 l...
Automated centrifuge for the processing of microplates and tubes; can be integrated into automated process using inexpensive robotics due to its unique sample handling platform....
... the first higher plant to be fully ... primary model organism for gene expression research ... microarray is derived from the ATH1 v.5 ... (TIGR) and from the Arabidopsis MPSS database ...
Biology Products: